Overview

Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer

Status:
Recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

The primary aim of this study is to test whether the combination of valproic acid with bevacizumab and oxaliplatin/fluoropyrimidine regimens (mFOLFOX6/mOXXEL) can prolong progression free survival (PFS) as compared with bevacizumab and oxaliplatin/fluoropyrimidine regimens alone as first-line treatment in patients with metastatic colorectal cancer with mutation of RAS.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute, Naples

Treatments:

Bevacizumab
Capecitabine
Fluorouracil
Oxaliplatin
Valproic Acid